Tags

Type your tag names separated by a space and hit enter

Epidemiology of tick-borne encephalitis (TBE) in Europe and its prevention by available vaccines.
Hum Vaccin Immunother 2013; 9(5):1163-71HV

Abstract

Tick-borne Encephalitis (TBE), which is caused by a Flavivirus, is the most common tick-transmitted disease in Central and Eastern Europe and Russia. Today, TBE is endemic in 27 European countries, and has become an international public health problem. The epidemiology of TBE is changing owing to various factors, such as improvements in diagnosis and case reporting, increased recreational activities in areas populated by ticks, and changes in climatic conditions affecting tick habitats. Vaccination remains the most effective protective measure against TBE for people living in risk zones, occupationally exposed subjects and travelers to endemic areas. The vaccines currently in use are FSME-Immun(®), Encepur(®), EnceVir(®) and TBE vaccine Moscow(®). The numerous studies performed on the efficacy and safety of these vaccines have shown a high level of immunogenicity and an excellent safety profile. Several studies have also shown a high level of cross-protection among strains belonging to different subtypes. In the present paper we attempted to describe the continuously changing epidemiology of TBE in European States and to overview clinical development of available vaccines paying particular attention on cross-protection elicited by the vaccines.

Authors+Show Affiliations

Department of Health Sciences; University of Genoa; Genoa, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

23377671

Citation

Amicizia, Daniela, et al. "Epidemiology of Tick-borne Encephalitis (TBE) in Europe and Its Prevention By Available Vaccines." Human Vaccines & Immunotherapeutics, vol. 9, no. 5, 2013, pp. 1163-71.
Amicizia D, Domnich A, Panatto D, et al. Epidemiology of tick-borne encephalitis (TBE) in Europe and its prevention by available vaccines. Hum Vaccin Immunother. 2013;9(5):1163-71.
Amicizia, D., Domnich, A., Panatto, D., Lai, P. L., Cristina, M. L., Avio, U., & Gasparini, R. (2013). Epidemiology of tick-borne encephalitis (TBE) in Europe and its prevention by available vaccines. Human Vaccines & Immunotherapeutics, 9(5), pp. 1163-71. doi:10.4161/hv.23802.
Amicizia D, et al. Epidemiology of Tick-borne Encephalitis (TBE) in Europe and Its Prevention By Available Vaccines. Hum Vaccin Immunother. 2013;9(5):1163-71. PubMed PMID: 23377671.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Epidemiology of tick-borne encephalitis (TBE) in Europe and its prevention by available vaccines. AU - Amicizia,Daniela, AU - Domnich,Alexander, AU - Panatto,Donatella, AU - Lai,Piero Luigi, AU - Cristina,Maria Luisa, AU - Avio,Ulderico, AU - Gasparini,Roberto, Y1 - 2013/02/01/ PY - 2013/2/5/entrez PY - 2013/2/5/pubmed PY - 2014/5/6/medline KW - TBE vaccines KW - epidemiology KW - prevention KW - tick-borne encephalitis KW - vaccine cross-protection SP - 1163 EP - 71 JF - Human vaccines & immunotherapeutics JO - Hum Vaccin Immunother VL - 9 IS - 5 N2 - Tick-borne Encephalitis (TBE), which is caused by a Flavivirus, is the most common tick-transmitted disease in Central and Eastern Europe and Russia. Today, TBE is endemic in 27 European countries, and has become an international public health problem. The epidemiology of TBE is changing owing to various factors, such as improvements in diagnosis and case reporting, increased recreational activities in areas populated by ticks, and changes in climatic conditions affecting tick habitats. Vaccination remains the most effective protective measure against TBE for people living in risk zones, occupationally exposed subjects and travelers to endemic areas. The vaccines currently in use are FSME-Immun(®), Encepur(®), EnceVir(®) and TBE vaccine Moscow(®). The numerous studies performed on the efficacy and safety of these vaccines have shown a high level of immunogenicity and an excellent safety profile. Several studies have also shown a high level of cross-protection among strains belonging to different subtypes. In the present paper we attempted to describe the continuously changing epidemiology of TBE in European States and to overview clinical development of available vaccines paying particular attention on cross-protection elicited by the vaccines. SN - 2164-554X UR - https://www.unboundmedicine.com/medline/citation/23377671/full_citation L2 - http://www.tandfonline.com/doi/full/10.4161/hv.23802 DB - PRIME DP - Unbound Medicine ER -